
    
      The study is designed as a multicenter, single-arm, open label, 12 months follow-up clinical
      trial. Men with localized prostate cancer will be treated with TOOKAD® Soluble VTP under
      general anesthesia.

      Patients will be followed-up for 12 months with patient questionnaires on QoL, erectile and
      urinary functions, clinical evaluation with study visits at 1, 3, 6 and 12 months , Prostate
      Specific Antigen(PSA) testing at 3, 6 and 12 months. In addition, they will have biopsy at 6
      months (± 2) and 12 months.
    
  